Interleukin-15 are associated with insulin resistance in postmenopausal women with metabolic syndrome

References

• Petri Nahas EA, Padoani NP, Nahas-Neto J, et al. Metabolic syndrome and its associated risk factors in Brazilian postmenopausal women. Climacteric. 2009;12(5):431–438.
   PubMed Web of Science ®Google Scholar
• Gurka MJ, Vishnu A, Santen RJ, et al. Progression of metabolic syndrome severity during the menopausal transition. JAHA. 2016 [cited 2022 Mar 8];5(8):5. Available from: https://www.ahajournals.org/doi/101161/JAHA.116.003609.
   Google Scholar
• Robeva R, Mladenović D, Vesković M, et al. The interplay between metabolic dysregulations and non-alcoholic fatty liver disease in women after menopause. Maturitas. 2021;151:22–30.
   PubMed Web of Science ®Google Scholar
• da Silva AA, do Carmo JM, Li X, et al. Role of hyperinsulinemia and insulin resistance in hypertension: metabolic syndrome revisited. Can J Cardiol. 2020;36(5):671–682.
   PubMed Web of Science ®Google Scholar
• Laudisio D, Muscogiuri G, Barrea L, et al. Obesity and breast cancer in premenopausal women: current evidence and future perspectives. Eur J Obstet Gynecol Reprod Biol. 2018;230:217–221.
   PubMed Web of Science ®Google Scholar
• Mili N, Paschou SA, Goulis DG, et al. Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations. Endocrine. 2021;74(3):478–497.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542(7640):177–185.
   PubMed Web of Science ®Google Scholar
• Garneau L, Aguer C. Role of myokines in the development of skeletal muscle insulin resistance and related metabolic defects in type 2 diabetes. Diabetes Metab. 2019;45(6):505–516.
   PubMed Web of Science ®Google Scholar
• Chow LS, Gerszten RE, Taylor JM, et al. Exerkines in health, resilience and disease. Nat Rev Endocrinol. 2022;18(5):273–289.
   PubMed Web of Science ®Google Scholar
• Duan Y, Li F, Wang W, et al. Interleukin-15 in obesity and metabolic dysfunction: current understanding and future perspectives. Obes Rev. 2017;18(10):1147–1158.
   PubMed Web of Science ®Google Scholar
• Ye J. Beneficial metabolic activities of inflammatory cytokine interleukin 15 in obesity and type 2 diabetes. Front Med. 2015;9(2):139–145.
   PubMed Web of Science ®Google Scholar
• Quinn LS, Anderson BG, Strait-Bodey L, et al. Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. Am J Physiol Endocrinol Metab. 2009;296(1):E191–E202.
   PubMed Web of Science ®Google Scholar
• Quinn LS, Strait-Bodey L, Anderson BG, et al. Interleukin-15 stimulates adiponectin secretion by 3T3-L1 adipocytes: evidence for a skeletal muscle-to-fat signaling pathway. Cell Biol Int. 2005;29(6):449–457.
   PubMed Web of Science ®Google Scholar
• Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8(8):457–465.
   PubMed Web of Science ®Google Scholar
• Nielsen AR, Hojman P, Erikstrup C, et al. Association between interleukin-15 and obesity: interleukin-15 as a potential regulator of fat mass. J Clin Endocrinol Metab. 2008;93(11):4486–4493.
   PubMed Web of Science ®Google Scholar
• Pérez-López A, Valadés D, Vázquez Martínez C, et al. Serum IL-15 and IL-15Rα levels are decreased in lean and obese physically active humans. Scand J Med Sci Sports. 2018;28(3):1113–1120.
   PubMed Web of Science ®Google Scholar
• Katsogiannos P, Kamble PG, Pereira MJ, et al. Changes in circulating cytokines and adipokines after RYGB in patients with and without type 2 diabetes. Obesity (Silver Spring). 2021;29(3):535–542.
   PubMed Web of Science ®Google Scholar
• Choi KM, Hwang SY, Han K, et al. Interleukin-15 and irisin serum concentrations are not related to cardiometabolic risk factors in patients with type 2 diabetes from Korea and Germany. Acta Diabetol. 2020;57(3):381–384.
   PubMed Web of Science ®Google Scholar
• Ciaraldi TP, Ryan AJ, Mudaliar SR, et al. Altered myokine secretion Is an intrinsic property of skeletal muscle in type 2 diabetes. Hribal ML, editor. PLoS One. 2016;11(7):e0158209.
   PubMed Web of Science ®Google Scholar
• Al-Shukaili A, AL-Ghafri S, Al-Marhoobi S, et al. Analysis of inflammatory mediators in type 2 diabetes patients. Int J Endocrinol. 2013;2013:976810–976817.
   PubMed Web of Science ®Google Scholar
• Dozio E, Malavazos AE, Vianello E, et al. Interleukin-15 and soluble interleukin-15 receptor α in coronary artery disease patients: association with epicardial fat and indices of adipose tissue distribution. Bonecchi R, editor. PLoS One. 2014;9(3):e90960.
   PubMed Web of Science ®Google Scholar
• Kaibe M, Ohishi M, Ito N, et al. Serum interleukin-15 concentration in patients with essential hypertension. Am J Hypertens. 2005;18(8):1019–1025.
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA. 2001;285(19):2486–2497.
   PubMed Web of Science ®Google Scholar
• Fahed G, Aoun L, Bou Zerdan M, et al. Metabolic syndrome: updates on pathophysiology and management in 2021. IJMS. 2022;23(2):786.
   Google Scholar
• Bueloni-Dias FN, Orsatti CL, Cangussu LM, et al. Isolated vitamin D supplementation improves the immune-inflammatory biomarkers in younger postmenopausal women: a randomized, double-blind, placebo-controlled trial. Menopause. 2018;25(8):897–903.
   PubMed Web of Science ®Google Scholar
• Bland JM, Altman DG. Best (but oft forgotten) practices: testing for treatment effects in randomized trials by separate analyses of changes from baseline in each group is a misleading approach. Am J Clin Nutr. 2015;102(5):991–994.
   PubMed Web of Science ®Google Scholar
• Li W, Li Y, Jin J. The essential function of IL-33 in metabolic regulation. Acta Biochim Biophys Sin (Shanghai). 2020;52(7):768–775.
   PubMed Web of Science ®Google Scholar
• Tu L, Yang L. IL-33 at the crossroads of metabolic disorders and immunity. Front Endocrinol (Lausanne). 2019;10(26):26.
   PubMedGoogle Scholar
• Loro E, Seifert EL, Moffat C, et al. IL-15Rα is a determinant of muscle fuel utilization, and its loss protects against obesity. Am J Physiol Regul Integr Comp Physiol. 2015;309(8):R835–R844.
   PubMed Web of Science ®Google Scholar
• Sun H, Ma Y, Gao M, et al. IL-15/sIL-15Rα gene transfer induces weight loss and improves glucose homeostasis in obese mice. Gene Ther. 2016;23(4):349–356.
   PubMed Web of Science ®Google Scholar
• Busquets S, Figueras M, Almendro V, et al. Interleukin-15 increases glucose uptake in skeletal muscle. An antidiabetogenic effect of the cytokine. Biochim Biophys Acta. 2006;1760(11):1613–1617.
   PubMed Web of Science ®Google Scholar
• Sun H, Liu D. Hydrodynamic delivery of interleukin 15 gene promotes resistance to high fat diet-induced obesity, fatty liver and improves glucose homeostasis. Gene Ther. 2015;22(4):341–347.
   PubMed Web of Science ®Google Scholar
• Krolopp JE, Thornton SM, Abbott MJ. IL-15 activates the Jak3/STAT3 signaling pathway to mediate glucose uptake in skeletal muscle cells. Front Physiol. 2016 [cited 2022 Mar 8];7:626. Available from: http://journal.frontiersin.org/article/103389/fphys.2016.00626/full.
   PubMed Web of Science ®Google Scholar
• Nadeau L, Patten DA, Caron A, et al. IL-15 improves skeletal muscle oxidative metabolism and glucose uptake in association with increased respiratory chain supercomplex formation and AMPK pathway activation. Biochim Biophys Acta Gen Subj. 2019;1863(2):395–407.
   PubMed Web of Science ®Google Scholar
• Fujimoto T, Sugimoto K, Takahashi T, et al. Overexpression of interleukin-15 exhibits improved glucose tolerance and promotes GLUT4 translocation via AMP-activated protein kinase pathway in skeletal muscle. Biochem Biophys Res Commun. 2019;509(4):994–1000.
   PubMed Web of Science ®Google Scholar